Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug

Stock Information for Ainos Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ainos Inc.

Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren's Syndrome
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.